Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rolontis Leads Hanmi’s Global Ambitions As ADVANCE Phase III Endpoint Met

Executive Summary

Rolontis, a novel, long-acting granulocyte colony-stimulating factor (G-CSF) licensed out to Spectrum Pharmaceuticals, has become Hanmi Pharmaceuticals' first drug developed with its proprietary platform to approach the regulatory filings stage in global markets.


Related Content

Spectrum Gears Up To File Rolontis, Stresses Patient Access
Other ASCO 2018 Highlights – It’s Not All IO
Hanmi Halts Olmutinib Development After Alliances Crumble
Lilly Halts Hanmi BTK Inhibitor Trial For RA, Mulls Other Indications
First Biosimilar Neulasta In Final Stages Of EMA Review Process
Poziotinib Shows Promise In EGFR Exon 20 Mutant NSCLC


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts